LC-MSD as a platform for inhalation product development
Choosing a testing
facility with LC-MSD
capability can save
significant amounts of
time and money for
pulmonary delivery
product development
projects.
According to an estimate produced by the Boston
Consulting Group in 2001, development of a new drug
cost nearly $900 million, of which more than $150
million was attributable to the chemistry component
alone. Given that costs at the time were rising at nearly
7.5% above general price inflation, it’s not unreasonable
to guess that chemistry costs are now well above
$200 million, and an average of 12 to 17 years elapses
between the discovery of a drug and its approval, when
it can start generating revenue. For inhalation products,
analytical development undoubtedly costs more
than for solid dosage and other drug forms due to
additional testing necessary for the delivery systems.